Vir Biotechnology to Host a Call on Sotrovimab’s Retained Activity Against the Omicron SARS-CoV-2 Variant

by NASDAQ Market News December 7, 2021

NASDAQ Market News
Click here to email author

Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19

Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 Variant

Ads